The first half of 2026 brought significant changes to FDA compounding oversight — changes that directly affect the availability, quality standards, and legal framework for compounded GLP-1 medications. Here's a chronological timeline of the key developments, what each one means, and where things stand heading into the second half of the year.
January 2026: Oral Wegovy Launch Reshapes the Market
Novo Nordisk's oral semaglutide formulation (oral Wegovy) launched for weight management, introducing the first FDA-approved needle-free option for patients who previously had only injectable choices. While not a regulatory change in compounding law, this market development shifted the competitive landscape by giving patients a brand-name alternative that addresses one of the main reasons patients chose compounded options: needle aversion.
Impact on compounding: Compounding pharmacies responded by emphasizing their advantages — lower cost, dosing flexibility, and formulation customization — rather than format convenience alone.
February 2026: FDA Warning Letters to Multiple Compounding Facilities
The FDA issued warning letters to several compounding pharmacies citing manufacturing deficiencies in GLP-1 preparations. The cited violations included potency testing failures, inadequate cleanroom maintenance, and documentation deficiencies. These actions signaled increased FDA scrutiny of the compounded GLP-1 sector specifically.
Impact on compounding: Quality-focused pharmacies used these warning letters as validation of their investment in higher standards. Patients became more aware of the importance of pharmacy verification. Some providers proactively communicated their clean inspection histories to differentiate themselves.
March 2026: Semaglutide Shortage Officially Resolved
The FDA officially resolved the semaglutide drug shortage, ending a period during which compounding of semaglutide was broadly permitted under the shortage provision of federal law. This resolution triggered a legal transition period for compounding pharmacies.
Impact on compounding: The shortage resolution didn't immediately end semaglutide compounding, but it changed the legal basis. 503B outsourcing facilities faced eventual restrictions on compounding products that are "essentially copies" of commercially available semaglutide. 503A pharmacies retained the ability to compound patient-specific prescriptions when a prescriber documents clinical need for a compounded formulation.
April 2026: FDA Proposes 503B Exclusion for GLP-1 Compounds
The FDA formally proposed adding certain GLP-1 receptor agonist formulations to the list of drugs that 503B outsourcing facilities cannot compound. The proposal included a 60-day public comment period, inviting input from patients, healthcare providers, pharmacists, and industry stakeholders.
Impact on compounding: This was the most consequential regulatory action of H1 2026 for the compounded GLP-1 market. It set up a clear distinction between 503A compounding (largely unaffected) and 503B compounding (potentially restricted). Providers began communicating transition plans to patients and securing alternative pharmacy partnerships.
April–May 2026: Industry Responds to Exclusion Proposal
The compounding industry, patient advocacy groups, telehealth platforms, and individual patients organized comment submissions during the public comment period. Key themes in the submitted comments included:
Patient access concerns: Thousands of patient comments described the importance of affordable compounded GLP-1 access and the financial barriers to brand-name medications.
Clinical differentiation arguments: Pharmacy organizations argued that formulations with meaningful clinical differences — such as added B12, alternative concentrations, or different delivery formats — should be exempt from exclusion because they're not "essentially copies."
Safety data: Both sides cited safety data — exclusion proponents pointing to FDA warning letters and quality concerns, while compounding advocates cited the strong safety record of accredited compounding operations.
May 2026: Updated USP <797> Compliance Enforcement
State Boards of Pharmacy increased enforcement of the revised USP <797> sterile compounding standards that took effect in late 2023. Pharmacies that hadn't fully implemented the updated requirements — including facility upgrades, updated beyond-use dating practices, and enhanced environmental monitoring — faced inspection deficiencies and potential enforcement actions.
Impact on compounding: This enforcement push raised the quality floor for all sterile compounding, including GLP-1 preparations. Pharmacies that had invested in USP <797> compliance early benefited from being ahead of the curve. Some smaller operations that hadn't completed their compliance upgrades faced difficult choices about continued operation.
June 2026: Comment Period Closes; ENDO 2026 Data Bolsters GLP-1 Support
The FDA's 503B exclusion comment period closed on June 29, 2026, after receiving tens of thousands of comments. Simultaneously, the ENDO 2026 conference (June 14–17 in Chicago) released landmark GLP-1 research including data on biological aging reversal, cancer risk reduction, and male fertility benefits — findings that reinforced the clinical significance of broad GLP-1 access.
Impact on compounding: The volume and content of public comments created a substantial record for the FDA to consider. The ENDO 2026 data strengthened the argument for maintaining broad access to GLP-1 medications, including compounded options. The FDA is expected to take several months to review comments before issuing a final rule.
Where Things Stand in July 2026
Heading into H2 2026, the regulatory landscape for compounded GLP-1s can be summarized:
| Factor | Current Status | Outlook |
|---|---|---|
| 503A compounding | Continues with clinical justification | Stable |
| 503B compounding | Currently operational; exclusion proposed | Final rule expected late 2026 / early 2027 |
| Semaglutide shortage | Officially resolved | No change expected |
| Quality enforcement | Increasing at both federal and state levels | Continued tightening |
| Brand-name competition | Growing (oral Wegovy, savings programs) | More options expected |
The Big Picture
H1 2026 was a period of regulatory clarification, not shutdown. The FDA is establishing clearer rules for which types of GLP-1 compounding will continue and under what conditions. For patients working with quality providers and verified pharmacies, compounded GLP-1 access remains viable. The trend is toward higher standards and greater accountability — which ultimately benefits patients.
What to Watch in H2 2026
Final 503B rule. The FDA's final decision on 503B exclusions will be the most significant regulatory event of the year for the compounded GLP-1 market. Timing is uncertain but likely before year-end.
Tirzepatide shortage status. The FDA's determination on tirzepatide availability could affect compounding eligibility for tirzepatide specifically.
Brand-name pricing moves. Novo Nordisk and Eli Lilly pricing decisions — including expanded savings programs and potential additional formulations — will affect the competitive dynamics between brand-name and compounded options.
State-level actions. Individual states may take their own positions on GLP-1 compounding, adding another layer to the regulatory landscape.